Similar articles

• [Clinical effects of NK 631 in malignant tumors of the oral cavity (author's transl)].

  Kawahira K, Dohhara Y, Sugihara K, Yamada K, Fujinami Y, Saku T, Yamashita S. Kawahira K, et al. Jpn J Antibiot. 1979 Jan;32(1):138-48. Jpn J Antibiot. 1979. PMID: 84884 Japanese. No abstract available.
• [Preoperative application of NK 631 for carcinoma of oral cavity (author's transl)].

  Yamamoto E, Sunakawa H, Kohama GI. Yamamoto E, et al. Jpn J Antibiot. 1979 Feb;32(2):253-8. Jpn J Antibiot. 1979. PMID: 86621 Japanese. No abstract available.
• [Clinical experiences with pepleomycin (NK 631) (author's transl)].

  Kusakari J, Sato Y, Saijo S, Tomioka S, Kawamoto K. Kusakari J, et al. Jpn J Antibiot. 1978 Nov;31(11):659-63. Jpn J Antibiot. 1978. PMID: 83402 Japanese. No abstract available.
• A review of clinical studies of pepleomycin.

  Oka S. Oka S. Recent Results Cancer Res. 1980;74:163-71. doi: 10.1007/978-3-642-81488-4_21. Recent Results Cancer Res. 1980. PMID: 6160600 Review.
• Discovery of clinical effect of bleomycin and its further development.

  Ichikawa T. Ichikawa T. Prog Biochem Pharmacol. 1976;11:143-57. Prog Biochem Pharmacol. 1976. PMID: 63959 Review. No abstract available.